AbbVie Inc. $ABBV Shares Bought by SVB Wealth LLC

SVB Wealth LLC lifted its position in shares of AbbVie Inc. (NYSE:ABBV) by 7.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 59,646 shares of the company’s stock after purchasing an additional 4,214 shares during the quarter. AbbVie makes up about 1.0% of SVB Wealth LLC’s investment portfolio, making the stock its 23rd largest position. SVB Wealth LLC’s holdings in AbbVie were worth $14,856,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Burk Holdings LLC bought a new position in AbbVie in the second quarter worth $30,000. Marquette Asset Management LLC boosted its stake in AbbVie by 52.2% during the second quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock worth $35,000 after buying an additional 48 shares in the last quarter. IMG Wealth Management Inc. boosted its stake in AbbVie by 3,060.0% during the second quarter. IMG Wealth Management Inc. now owns 158 shares of the company’s stock worth $40,000 after buying an additional 153 shares in the last quarter. Principia Wealth Advisory LLC increased its holdings in AbbVie by 38.9% in the 2nd quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock valued at $40,000 after buying an additional 44 shares during the period. Finally, Tacita Capital Inc bought a new stake in AbbVie in the 2nd quarter valued at $42,000. 70.23% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Bank of America restated a “buy” rating on shares of AbbVie in a research note on Tuesday, September 8th. BNP Paribas Exane raised their price objective on shares of AbbVie from $218.00 to $247.00 and gave the stock a “neutral” rating in a report on Tuesday, August 11th. Barclays lifted their target price on shares of AbbVie from $300.00 to $325.00 and gave the company an “overweight” rating in a research report on Wednesday, October 21st. JPMorgan Chase & Co. upped their target price on shares of AbbVie from $285.00 to $300.00 and gave the company an “overweight” rating in a research note on Thursday, October 8th. Finally, HSBC increased their price target on shares of AbbVie from $300.00 to $315.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $297.46.

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $294.75 on Friday. The company’s fifty day moving average is $274.82 and its 200-day moving average is $240.55. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $302.93. The company has a market capitalization of $521.01 billion, a PE ratio of 50.73, a P/E/G ratio of 1.34 and a beta of 0.20.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, October 30th. The company reported $3.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.73 by $0.09. AbbVie had a net margin of 15.67% and a negative return on equity of 450.55%. The business had revenue of $17.40 billion during the quarter, compared to analysts’ expectations of $17.32 billion. During the same quarter last year, the company posted $1.86 EPS. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. On average, analysts forecast that AbbVie Inc. will post 13.98 EPS for the current year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 16th. Shareholders of record on Friday, January 15th will be paid a dividend of $1.82 per share. This is a positive change from AbbVie’s previous quarterly dividend of $1.73. This represents a $7.28 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Friday, January 15th. AbbVie’s payout ratio is currently 119.10%.

Insiders Place Their Bets

In other AbbVie news, EVP Jeffrey Stewart sold 40,619 shares of the company’s stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $293.60, for a total transaction of $11,925,738.40. Following the sale, the executive vice president directly owned 83,171 shares of the company’s stock, valued at approximately $24,419,005.60. This represents a 32.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.06% of the company’s stock.

Trending Headlines about AbbVie

Here are a few of the latest headlines about ABBV:

• Positive Sentiment: AbbVie’s immunology sales rose 16.6% in the third quarter, with Skyrizi and Rinvoq growth more than offsetting Humira’s decline. The performance has supported higher 2026 sales expectations and strengthens the case that newer drugs can sustain growth. How Did AbbVie’s Immunology Franchise Fare in Q3?
• Neutral Sentiment: AbbVie’s licensing agreement with Nxera Pharma for an inflammatory bowel disease program adds a potential pipeline opportunity, but requires AbbVie to make an upfront payment and could involve substantial milestone payments. The deal’s longer-term value depends on development and commercial success. AbbVie Deal Altering the Investment Case for Nxera Pharma?
• Neutral Sentiment: A Crohn’s disease study update drew coverage describing its likely near-term stock impact as limited; it does not appear to materially change the immediate investment outlook. AbbVie Crohn’s Disease Study Update

AbbVie Profile

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.